{"id":979752,"date":"2026-07-08T10:24:47","date_gmt":"2026-07-08T14:24:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-on-adma-biologics-inc-adma-join-class-action-suit-seeking-recovery-contact-levi-korsinsky\/"},"modified":"2026-07-08T10:24:47","modified_gmt":"2026-07-08T14:24:47","slug":"lost-money-on-adma-biologics-inc-adma-join-class-action-suit-seeking-recovery-contact-levi-korsinsky","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-on-adma-biologics-inc-adma-join-class-action-suit-seeking-recovery-contact-levi-korsinsky\/","title":{"rendered":"Lost Money on ADMA BIOLOGICS, INC. (ADMA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n ADMA Biologics projected 20% ASCENIV revenue growth in 2025, but a short-seller report alleges<\/span> the real figure was a 3% decline, with the gap driven entirely by an alleged<\/span> channel stuffing scheme.<\/i>\n <\/p>\n

\n NEW YORK<\/span>, July 8, 2026<\/span> \/PRNewswire\/ — Levi & Korsinsky, LLP highlights the contrast between ADMA Biologics, Inc.’s (NASDAQ: ADMA) public growth projections and the results alleged<\/span> by independent research. A securities class action has been filed on behalf of investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. Find out if you qualify to recover losses from ADMA’s alleged<\/span> misrepresentations<\/a>. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/a> or (212) 363-7500.<\/p>\n

\n

\n \"Levi\n <\/p>\n<\/p><\/div>\n

ADMA reported ASCENIV net revenues of $362.5 million for 2025, reflecting approximately 20% year-over-year growth. According to Culper Research, absent an alleged<\/span> channel stuffing scheme, ASCENIV revenues actually declined approximately 3%. The lead plaintiff deadline is August 10, 2026.<\/p>\n

\n The Promise<\/b>\n <\/p>\n

ADMA told investors a compelling story throughout the Class Period. ASCENIV, the Company’s flagship immunoglobulin therapy, was presented as a premium specialty biologic commanding approximately 900 per gram. SEC filings showed ASCENIV revenues surging from 92.6 million in 2023 to $362.5 million in 2025. The Company certified that its disclosure controls and internal controls over financial reporting were effective at the reasonable assurance level. Revenue recognition policies stated that product revenue was recognized when the customer had control over the product and the performance obligation was satisfied.<\/p>\n

\n The Reality<\/b>\n <\/p>\n

Culper Research’s March 24, 2026 report painted a starkly different picture. The action claims that payors treated ASCENIV as functionally identical to standard IVIGs available at a fraction of the price, imposing strict prior authorization requirements, step edits, and outright denials. Providers allegedly<\/span> slowed their ordering. Distributors were reportedly left holding excess inventory. Yet ADMA’s reported revenue figures continued climbing.<\/p>\n

\n The Numbers: Promised vs. Actual<\/b>\n <\/p>\n